SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of abrupt layoffs affecting roughly 550 workers in India, with additional cuts in the Philippines, have raised fears that a client project was scaled back and could weigh on revenue, particularly given Innodatas customer concentration; the company has not clarified the impact. Traders are divided between viewing the selloff as an overreaction or an efficiency shift and worrying about a lost major account, with many awaiting earnings and managements explanation.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotles quarterly report sparked a rally after same-store sales growth topped expectations, though earnings fell short and margins weakened. Traders are watching whether the post-report momentum continues, while others remain cautious about softer sales trends and cost pressures.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI is drawing attention around speculation that a bank charter and expanded USD1 stablecoin use could support a rebound, with bullish traders also pointing to limited circulating supply. Others are skeptical, citing the tokens weak performance and concerns that the Trump family has profited while holders absorb losses.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circles CFO is preparing to step down, while co-founder and director Sean Neville has resigned from the board, prompting concern about leadership stability. Traders disagree on whether the departures are an orderly transition or a warning sign, with USDC growth and competition also weighing on sentiment.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 results, with improving profitability, margins and cash generation, drove a sharp rebound and fueled speculation that heavy short interest could amplify the move. Bulls see signs of a turnaround, while skeptics point to declining revenue and BetterHelps ongoing weakness and question whether the rally is justified.

Pump.fun (PUMP) is a cryptocurrency launched in 2025and operates on the Solana platform. Pump.fun has a current supply of 824,932,291,477.509362 with 460,045,468,948.538529 in circulation. The last known price of Pump.fun is 0.00419537 USD and is up 0.39 over the last 24 hours. It is currently trading on 413 active market(s) with $87,549,521.45 traded over the last 24 hours. More information can be found at https://pump.fun/.

Pump.fun

PUMP.fun is drawing attention for a volatile rebound and anticipated breakout, with traders highlighting the tokens buyback-and-burn mechanism and the platforms activity as bullish arguments. Others remain skeptical, pointing to sharp selloffs, weak participation, and the risks of meme-coin speculation.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October delivery update is driving attention, with traders highlighting record deliveries and rapid overseas growth while watching whether that pace can support the companys Q4 outlook. The reaction is mixed: some see evidence of growth momentum, while others question margins and profitability amid continued weakness in the shares.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention for a recent technical rebound, with traders highlighting a breakout that held and discussing bullish swing trades and call options. Others question the rally given high rates and weak housing conditions, framing the move as sector rotation rather than evidence of a housing recovery.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Treasury-yield volatility and uncertainty over the Feds rate path dominate discussion, with inflation, fiscal borrowing and AI-related debt financing adding to concerns about pressure on Treasuries. Traders are divided between expecting higher-for-longer yields to weigh on IEF and anticipating a bond rebound if yields ease.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes post-earnings selloff and new 52-week low dominate discussion, despite traders noting an earnings beat and a modestly improved outlook. The bearish reaction reflects concerns about weak underlying growth, limited traction in higher-end driver-assistance programs, and competition; some holders argue the results and cash position make the decline excessive.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 17,461 shares of common stock and...

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application...

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law FirmPR NewswireNEW YORK, Sept. 30, 2026NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Equity

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.


Scholar Rock (NASDAQ: SRRK; the Company) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and...

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets 

On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.


Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours  

FDA approved Isembyld for patients age two and older who already take certain spinal muscular atrophy drugs. 


Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for...

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug...

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

Neutral Sentiment

<ul class="summary-bullets"><li>Bristol Myers Squibb faces an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy.</li><li>Scholar Rock’s Isembyld and Biofrontera's (BFRI) Ameluz received FDA clearance ahead of their scheduled late-September PDUFA dates.</li><li>Mirum Pharmaceuticals’ Atebrioz got FDA approval on Friday for patients aged 12-18 with an ultra-rare genetic disease.</li></ul>Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-September decisions have already received regulatory clearance.Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) awaits an FDA decision on expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle blocks blood flow. Stockholm-listed Egetis Therapeutics also faces a decision on Emcitate for MCT8 deficiency, a rare genetic disorder that affects how thyroid hormones reach the brain and other tissues.Meanwhile, Biofrontera (BFRI) and Scholar Rock (SRRK) entered the week with decisions originally scheduled for this period, while Mirum Pharmaceuticals (MIRM) and Incyte (INCY) received FDA approval for Atebrioz late last week.A PDUFA date is the target deadline by which the FDA aims to complete its review of a drug application.<img src="https://news.stocktwits-cdn.com/4_Hpst_fda_decisions_this_week_1_7833148823.png" alt="4Hpst-fda-decisions-this-week- (1).png"><h2 class="st-heading-2">Bristol Myers Awaits Camzyos Label Expansion</h2>The FDA is scheduled to make a decision on Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) on September 30. The regulatory body will decide whether to expand the use of Camzyos (Mavacamten) to adolescents ages 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Obstructive HCM is a condition in which the heart muscle becomes abnormally thick, potentially blocking blood flow out of the heart. Patients can experience shortness of breath, fatigue and chest pain.Camzyos is already FDA-approved for certain adults with symptomatic oHCM. Bristol Myers said the safety profile among adolescents was similar to that previously observed in adults.If cleared, Camzyos would become the first cardiac myosin inhibitor approved in the U.S. for adolescents with oHCM, according to the company.<h2 class="st-heading-2">Egetis Awaits FDA Decision On Rare Genetic Disorder Drug</h2>Egetis Therapeutics faces a September 28 decision on Emcitate for MCT8 deficiency.If approved, Emcitate would become the first FDA-approved treatment for MCT8 deficiency in the U.S. The drug is already approved in the European Union, and the FDA has already granted the application Priority Review. Emcitate has also received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations from the FDA.<h2 class="st-heading-2">FDA Already Acted On Several Late-September Decisions</h2>Several other drugs that had been heading toward FDA decisions around this week have already received regulatory clearance.Scholar Rock’s (SRRK) Isembyld was scheduled for a September 30 PDUFA date, but the FDA approved the treatment on Sept. 11 for adults and children aged two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.Spinal muscular atrophy is a rare genetic disease that causes progressive muscle weakness and loss of motor function. Scholar Rock said Isembyld is the first and only muscle-targeted treatment approved for SMA. However, SRRK shares are down more than 12% since the approval.Biofrontera’s (BFRI) Ameluz also received an FDA decision ahead of its September 28 PDUFA date. The label expansion covers Ameluz photodynamic therapy for superficial basal cell carcinoma, a common form of skin cancer. BFRI shares have seen an even sharper decline, down 23% since the FDA decision on September 14.<h2 class="st-heading-2">Mirum Gets FOP Drug Approval</h2>On Friday, the FDA approved Mirum Pharmaceuticals’ (MIRM) Atebrioz for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disease that causes bone to form in muscles and other soft tissues, gradually restricting movement.Mirum expects Atebrioz to become available in the U.S. in October.The biotech firm acquired worldwide rights to Atebrioz from Incyte (INCY) earlier this year. Incyte remains eligible for milestone payments and royalties from the drug.MIRM shares closed Friday’s session 0.4% higher and are currently trading up 3% in pre-market.<h2 class="st-heading-2">How Have BFRI, <a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>, SRRK, MIRM And INCY Performed YTD?</h2><img src="https://news.stocktwits-cdn.com/Biotech_63ba5c5882.png" alt="Biotech.png">Among these stocks, Biofrontera (BFRI) has gained the most this year, rising nearly 63%, followed by Incyte (INCY) at more than 22% and Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) at about 18%. Scholar Rock (SRRK) and Mirum Pharmaceuticals (MIRM) have each gained roughly 13%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/critical-minerals-wrap-crml-grml-surge-on-greenland-deal-us-stockpile-push-accelerates-as-trump-xi-talks-put-rare-earths-in-spotlight/cZMg2lHRBOY">Critical Minerals Wrap: CRML, GRML Surge On Greenland Deal, US Stockpile Push Accelerates As Trump-Xi Talks Put Rare Earths In Spotlight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-S

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals 

Biofrontera Inc

Bristol-Myers Squibb Co.

Incyte Corp.

Mirum Pharmaceuticals Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$43.90
Prev Close	$44.18
Open	$44.04
Dividend Yield	0.00%
50-Day Moving Average	$48.47
Beta	1.29
Avg. Volume	2.17M
PE Ratio	-12.72

52-Week High	$61.76
52-Week Low	$27.07
Market Capitalization	$5.35B
EPS (Annual)	-$3.30
Price to Book	21.03
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRRK Fundamentals